CREATE: Cross-tumoral Phase 2 With Crizotinib

General inclusion criteria: * Locally advanced and/or metastatic anaplastic large cell lymphoma * Locally advanced and/or metastatic inflammatory myofibroblastic tumor * Locally advanced and/or metastatic papillary renal cell carcinoma type 1 * Locally advanced and/or metastatic alveolar soft part sarcoma * Locally advanced and/or metastatic clear cell sarcoma * Locally advanced and/or metastatic alveolar rhabdomyosarcoma. * The above malignancies must be incurable by conventional surgery, radiotherapy, systemic therapy or any other means. * Proven presence of specific ALK and/or MET pathway alteration in tumor tissue is not mandatory for patient registration. * Availability of tumor material for central pathology review * Written informed consent * Measurable disease according to RECIST 1.1 * Patients with brain metastases are eligible if treated and/or neurologically stable with no ongoing requirement for corticosteroids (off steroids for at least 2 weeks) and not taking contraindicated medications. Absence of spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function. * No carcinomatous meningitis or leptomeningeal disease. * Any previous systemic anticancer therapy must have been completed at least 4 weeks prior to initiation of study medication. * No treatment with any other investigational drug within the past 4 weeks or within less than 4 half-life times of the investigational drug before treatment w…